American Society of Hematology

SHERPA: Blue

People

  1. Park
    Park
  2. Sadelain
    Sadelain
  3. Wang
    Wang
  4. Curran
    Curran
  5. Giralt
    Giralt
  6. Palomba
    Palomba
  7. Bernal
    Bernal
  8. Perales
    Perales
  9. Sauter
    Sauter
  10. Shah
    Shah

Groups

  1. Adult Leukemia (79)
  2. Center for Hematologic Malignancies (79)
  3. Department of Medicine (79)
  4. GSK Faculty (79)
  5. Hematologic Malignancies Research (79)
  6. Hematologic Malignancies, Division of (79)
  7. Sloan Kettering Institute Faculty (43)
  8. Molecular Pharmacology and Chemistry Program Faculty (40)
  9. Hematology-Oncology Fellows (28)
  10. Nursing (25)
Search Within
  1. "Renier Brentjens"
Formats
  1. Meeting Abstract (65)
  2. Journal Article (14)
Groups
  1. Adult Leukemia (79)
  2. Center for Hematologic Malignancies (79)
  3. Department of Medicine (79)
  4. GSK Faculty (79)
  5. Hematologic Malignancies Research (79)
  6. Hematologic Malignancies, Division of (79)

More Groups

People
  1. Renier Brentjens (79)
  2. Jae Park (41)
  3. Michel Sadelain (35)
  4. Isabelle Riviere (33)
  5. Xiuyan Wang (23)
  6. Craig Sauter (21)

More People

Years
  1. 2023 (2)
  2. 2021 (6)
  3. 2020 (3)
  4. 2019 (7)
  5. 2018 (7)
  6. 2017 (5)

More Years

Publications
  1. Blood (74)
  2. Blood Advances (4)
  3. Hematology-American Society of Hematology Education Program (1)

Results (79)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Manufacturing, characterization and anti-tumor activity of allogeneic CD19-CAR cytokine-induced killer (CIK) cells engineered with non-viral sleeping beauty transposon system and armored with IL-18
    Meeting Abstract

    Contreras-Ruiz, L.; Pace, B.; Kohnke, D. E.; Viruet, L.; Adams, M.; Krisko, J. F.; Leesnitzer, N.; Velie, M.; Tettamanti, S.; Pisani, I.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • A phase II trial of prophylactic anakinra to prevent neurotoxicity in patients receiving anti-CD19 CAR T-cell therapy for relapsed or refractory lymphoma: Final results from cohort 2
    Meeting Abstract

    Nath, K.; Devlin, S. M.; Sauter, C. S.; Palomba, M. L.; Shah, G. L.; Dahi, P. B.; Lin, R. J.; Scordo, M.; Perales, M. A.; Leslie, L. A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • The intestinal microbiota correlates with response and toxicity after CAR T cell therapy in patients with B-cell malignancies
    Meeting Abstract

    Smith, M.; Dai, A.; Ghilardi, G.; Amelsberg, K.; Devlin, S. M.; Pajarillo, R.; Slingerland, J. B.; Beghi, S.; Herrera, P. S.; Giardina, P. A.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Five-year experience using bridging radiotherapy prior to chimeric antigen receptor (CAR) T-cell therapies for B-cell malignancies at Memorial Sloan Kettering Cancer Center
    Meeting Abstract

    Silverman, E. A.; Hubbeling, H.; Palomba, M. L.; Wijetunga, N. A.; Tringale, K.; Lebow, E.; Tomas, A. A.; Shouval, R.; Batlevi, C. L.; Brentjens, R. J.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Phase I first-in-class trial of MCARH109, a G protein coupled receptor class C group 5 member D (GPRC5D) targeted CAR T cell therapy in patients with relapsed or refractory multiple myeloma
    Meeting Abstract

    Mailankody, S.; Diamonte, C.; Fitzgerald, L.; Kane, P.; Wang, X.; Sikder, D. S.; Senechal, B.; Bermudez, V. P.; Frias, D.; Morgan, J.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Lesion characteristics and patterns of failure in diffuse large B cell lymphoma patients treated with bridging radiotherapy prior to chimeric antigen receptor T cell therapy
    Meeting Abstract

    Hubbeling, H.; Silverman, E. A.; Wijetunga, N. A.; Palomba, M. L.; Tringale, K.; Lebow, E.; Tomas, A. A.; Shouval, R.; Batlevi, C. L.; Brentjens, R. J.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells
    Journal Article

    Pennisi, M.; Sanchez-Escamilla, M.; Flynn, J. R.; Shouval, R.; Alarcon Tomas, A.; Silverberg, M. L.; Batlevi, C.; Brentjens, R. J.; Dahi, P. B.; Devlin, S. M.; more...
    Blood Advances (2021)

    Fulltext@MSK | Save
  • Interventions and outcomes of adult patients with B-ALL progressing after CD19 chimeric antigen receptor T-cell therapy
    Journal Article

    Wudhikarn, K.; Flynn, J. R.; Rivière, I.; Gönen, M.; Wang, X.; Senechal, B.; Curran, K. J.; Roshal, M.; Maslak, P. G.; Geyer, M. B.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • A phase I study of CD19-targeted 19(T2)28z1xx CAR T cells in adult patients with relapsed or refractory B-cell malignancies
    Meeting Abstract

    Park, J. H.; Riviere, I.; Sikder, D. S.; Bermudez, V. P.; Senechal, B.; Wang, X.; Auchincloss, T. H.; Diamonte, C.; Halton, E.; Palomba, M. L.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies
    Journal Article

    Jain, T.; Knezevic, A.; Pennisi, M.; Chen, Y.; Ruiz, J. D.; Purdon, T. J.; Devlin, S. M.; Smith, M.; Shah, G. L.; Halton, E.; more...
    Blood Advances (2020)

    Fulltext@MSK | Save